+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
MALE
ID07885423

Evaluation of the ACP3-Targeted 68Ga-XMFH01 Dual PET and Fluorescence Imaging Probe for Prostate Cancer Surgery Guidance

Led by The First Affiliated Hospital of Xiamen University · Updated on 2026-10-26

25

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating 68Ga-XMFH01, a new imaging probe that targets ACP3, in patients with prostate cancer. This study aims to assess how well this dual-modality probe works for preoperative PETCT scans and for guiding surgery using fluorescence imaging. The goal is to see if this imaging method can improve tumor detection and surgical precision in prostate cancer patients. Participants will receive a single intravenous injection of 68Ga-XMFH01 before surgery. They will undergo PETCT imaging to locate tumor lesions and measure tracer uptake. During surgery, fluorescence imaging will help guide the removal of cancerous tissue and assess surgical margins. The study will compare imaging results with tissue examination after surgery to evaluate diagnostic accuracy and safety. Throughout the study, participants will follow a schedule of visits and imaging assessments including PETCT scans and intraoperative imaging. Researchers will monitor the concordance of fluorescence imaging with pathology results for surgical margins and lymph nodes. The main outcome is diagnostic efficacy assessed one month after surgery. Safety and feasibility of this imaging approach will also be closely observed. The study runs from October 2026 to September 2027.

CONDITIONS

Brief Title

68Ga-XMFH01 PET/Fluorescence Imaging in Prostate Cancer

Research Team

L

Liang Zhao, MD

H

Haojun Chen, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here